Netflix Realigns Pricing Strategy In Australia, Ends Basic Plan For New Members

Netflix is ending its Basic, ad-free subscription plan in Australia and several other countries, impacting new and returning subscribers.

In an unexpected move, streaming giant Netflix Inc. (NASDAQ:NFLX) has decided to cease its most budget-friendly, ad-free subscription plan in several countries, including Australia.

What Happened: Netflix is discontinuing the Basic plan, previously priced at $10.99 monthly for Australian users. This change will affect new and returning subscribers, but current users will retain their existing plans, reported 9News.

Netflix mentioned in a shareholder letter that company growth is fueled by improvements in their services, such as dual streaming, high-definition video, and a programming catalog comparable to other plans. 

Earlier, discontinuing the Basic plan in the U.S., U.K., Italy, and Canada reportedly increased the uptake of their ads and Standard plans.

See Also: Elon Musk’s 75-Year-Old Mother Says She Sleeps on ‘Mattresses Or Blankets On The Floor Or In The Garage’

The company plans to initiate the same changes in Germany, Spain, Japan, Mexico, Australia, and Brazil next week. Moreover, they aim to launch downloads next month and incorporate the ads plan in device and ISP partner bundles.

The Standard with ads plan, priced at $6.99 per month, is the least expensive. The Standard and Premium plans follow at $16.99 and $22.99 monthly.

Additional members can join the top two tiers for an extra $7.99 per month.

Why It Matters: Netflix’s decision to end the Basic plan comes on the heels of a reported price increase for certain streaming plans in the U.S., U.K., and France, coinciding with a growth in new customer sign-ups. 

As per a Benzinga report, the premium ad-free plan in the U.S. increased by $3 per month to $22.99. However, the entry-level, ad-supported tier remained at $6.99 per month.

This move also follows the company’s strong Q3 results, where Netflix reported a 7.8% YoY increase in revenue to $8.54 billion, exceeding the consensus estimate. The company’s earnings also beat the consensus estimate, rising from $3.10 to $3.73 per share. 

Photo by Kaspars Grinvalds on Shutterstock

Check out more of Benzinga’s Consumer Tech coverage by following this link.

Read Next: No Legit Excuse For Positive THC Test, New Rules Double Weed License Fees & Latest Reg Updates


Engineered by Benzinga Neuro, Edited by
Ananya Gairola


The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.
Learn more.


Total
0
Shares
Related Posts
Read More

Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting

– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma –– Preclinical data presented for novel

SGEN